0001654954-22-008784.txt : 20220624 0001654954-22-008784.hdr.sgml : 20220624 20220624193207 ACCESSION NUMBER: 0001654954-22-008784 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220622 FILED AS OF DATE: 20220624 DATE AS OF CHANGE: 20220624 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WILLS STEPHEN T CENTRAL INDEX KEY: 0001103883 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15543 FILM NUMBER: 221041356 MAIL ADDRESS: STREET 1: PALATIN TECHNOLOGIES, INC. STREET 2: 4B CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PALATIN TECHNOLOGIES INC CENTRAL INDEX KEY: 0000911216 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 954078884 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 4B CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: 609-495-2200 MAIL ADDRESS: STREET 1: 4B CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: INTERFILM INC DATE OF NAME CHANGE: 19930825 4 1 section16.xml PRIMARY DOCUMENT X0306 4 2022-06-22 0000911216 PALATIN TECHNOLOGIES INC PTN 0001103883 WILLS STEPHEN T PALATIN TECHNOLOGIES, INC. 4B CEDAR BROOK DRIVE CRANBURY NJ 08512 false true false false Executive VP and CFO/COO Common Stock 2022-06-22 4 A false 395000 0 A 9109100 D Common Stock 2022-06-22 4 A false 47457 0 A 9156557 D Common Stock 2022-06-22 4 A false 127414 0 A 9283971 D Common Stock 2022-06-22 4 A false 36028 0 A 9319999 D Stock Option (Right to Buy) 0.29 2022-06-22 4 A false 587500 0 A 2026-06-22 2032-06-22 Common Stock 587500 587500 D Stock Option (Right to Buy) 0.58 2022-06-22 4 A false 211136 0 A 2022-06-22 2030-06-22 Common Stock 211136 211136 D Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 22, 2023. Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 16, 2020, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 22, 2021, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. The options vest at the rate of 25% per year, starting on June 22, 2023. Stock options granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. The performance condition stock option grant, made June 16, 2020, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of stock option shares for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi. /s/ Stephen T. Wills by Stephen A. Slusher, Attorney-in-Fact 2022-06-24